Pharmaceutical Preparations · DE · CIK 1326732
Xencor discovers and develops engineered antibody therapeutics for cancer and autoimmune diseases using protein engineering
Comparable business profile · signals at a glance
In the 90 days to Mar 6, 2026: 4 sold $3.5M.
| Date | Insider | Action | Shares | Price | Value |
|---|---|---|---|---|---|
| Mar 6, 2026 | Dahiyat Bassil IPRESIDENT & CEO | Sell | 6,606 | $11.02 | $73K |
| Mar 6, 2026 | Desjarlais John RSR. VICE PRESIDENT & CSO | Sell | 2,502 | $11.02 | $28K |
| Mar 6, 2026 | Eckert CeliaSVP, GENERAL COUNSEL | Sell | 1,767 | $11.02 | $19K |
| Mar 5, 2026 | Dahiyat Bassil IPRESIDENT & CEO | Sell | 14,870 | $11.25 | $167K |
| Mar 5, 2026 | Desjarlais John RSR. VICE PRESIDENT & CSO | Sell | 4,118 | $11.25 | $46K |
| Mar 5, 2026 | Eckert CeliaSVP, GENERAL COUNSEL | Sell | 3,244 | $11.25 | $36K |
| Mar 5, 2026 | Cornelissen Bart JanSR. VICE PRESIDENT & CFO | Sell | 2,517 | $11.25 | $28K |
| Mar 3, 2026 | Dahiyat Bassil IPRESIDENT & CEO | Sell | 6,758 | $11.90 | $80K |
| Mar 3, 2026 | Desjarlais John RSR. VICE PRESIDENT & CSO | Sell | 2,663 | $11.90 | $32K |
| Mar 3, 2026 | Eckert CeliaSVP, GENERAL COUNSEL | Sell | 1,492 | $11.90 | $18K |
| Dec 19, 2025 | Dahiyat Bassil IPRESIDENT & CEO | Sell | 114,377 | $15.71 | $1.8M |
| Dec 19, 2025 | Desjarlais John RSR. VICE PRESIDENT & CSO | Sell | 73,367 | $15.72 | $1.2M |
Open-market buys & sells (Form 4, transaction codes P/S). Source: SEC structured insider data.